CareDx Announces Third KOAR Analysis Published in Transplantation

What happened

CareDx announced that a third analysis from the KOAR registry was published in Transplantation. It studied 1,137 kidney transplant recipients across 56 centers, grouping them by early AlloSure Kidney donor-derived cell-free DNA levels and linking those groups to three-year outcomes.

Confirmed

Global impact / market context

If early AlloSure Kidney results reliably signal later kidney problems, doctors may use the test sooner after transplant. That could support wider use of CareDx's testing in transplant care, which matters because more testing volume means more revenue for the company.

Analyst inference

CareDx sells specialized transplant tests, so published research supporting how doctors read those tests can help defend pricing and adoption against competing tests. The study covers many centers but is observational, meaning it shows links, not proof that testing itself changes patient outcomes.

Analyst inference

What to watch

1. Watch whether the full Transplantation article details the three-year rates of allograft dysfunction and graft loss for each AlloSure Kidney trajectory group, since the supplied text only describes the methods. Confirmed
2. Watch for CareDx or study authors to propose new clinical guidance on interpreting early AlloSure Kidney elevations, which could shape how transplant centers order and act on the test. Proposed
3. Watch transplant center adoption and test reimbursement decisions, because broader insurance coverage and routine early testing would raise CareDx test volume, revenue, and likely spending on sales and marketing. Analyst inference

Evidence

• Original source link unavailable